Literature DB >> 8495408

Characterization of insulin-like growth factor 1 in human primary brain tumors.

A C Sandberg-Nordqvist1, P A Ståhlbom, M Reinecke, V P Collins, H von Holst, V Sara.   

Abstract

Insulin-like growth factor 1 (IGF-1) is involved in the regulation of brain development and has been suggested as an autocrine stimulator of brain tumor cell proliferation. This study demonstrates the expression of IGF-1 in tumor tissue from human gliomas and one esthesioneuroblastoma. Using immunohistochemistry, expression of an IGF-1-like peptide was localized in tumor cells of 6 of the 9 gliomas examined as well as the esthesioneuroblastoma. From one anaplastic oligodendroglioma (which showed strong IGF-1 immunostaining) the IGF-1 transcripts were characterized after isolation of mRNA followed by amplification using the reverse transcriptase-polymerase chain reaction. Two IGF-1 complementary DNAs resulting from alternative splicing of the IGF-1 primary transcript were identified. These transcripts encode two different precursor proteins which correspond to Ea IGF-1 and Eb IGF-1. The significance of IGF-1 alternative mRNA splicing pathways remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495408

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins.

Authors:  S Sultana; R Zhou; M S Sadagopan; O Skalli
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

Review 2.  The IGF/IGFBP system in CNS malignancy.

Authors:  W Zumkeller; M Westphal
Journal:  Mol Pathol       Date:  2001-08

3.  The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo.

Authors:  Peiyu Pu; Chunsheng Kang; Jie Li; Hao Jiang; Jinquan Cheng
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cells: modulation of insulin-like growth factor-I receptor (IGF-IR) expression.

Authors:  K A Naidu; J L Tang; K A Naidu; L D Prockop; S V Nicosia; D Coppola
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

5.  Growth factor receptors signaling in glioblastoma cells: therapeutic implications.

Authors:  Mia Carapancea; Oana Alexandru; Ani S Fetea; Laura Dragutescu; Juan Castro; Ada Georgescu; A Popa-Wagner; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2008-11-30       Impact factor: 4.130

6.  Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas.

Authors:  Pei-Fang Wu; Wen-Chang Huang; James Chih-Hsin Yang; Yen-Shen Lu; Jin-Yuan Shih; Shang-Gin Wu; Ching-Hung Lin; Ann-Lii Cheng
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

7.  IGF-IR: a new prognostic biomarker for human glioblastoma.

Authors:  C Maris; N D'Haene; A-L Trépant; M Le Mercier; S Sauvage; J Allard; S Rorive; P Demetter; C Decaestecker; I Salmon
Journal:  Br J Cancer       Date:  2015-08-20       Impact factor: 7.640

8.  Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.

Authors:  Eva Serna; José Manuel Morales; Manuel Mata; José Gonzalez-Darder; Teresa San Miguel; Rosario Gil-Benso; Concha Lopez-Gines; Miguel Cerda-Nicolas; Daniel Monleon
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

9.  Aberrant signaling pathways in glioma.

Authors:  Mitsutoshi Nakada; Daisuke Kita; Takuya Watanabe; Yutaka Hayashi; Lei Teng; Ilya V Pyko; Jun-Ichiro Hamada
Journal:  Cancers (Basel)       Date:  2011-08-10       Impact factor: 6.639

Review 10.  Targeting cellular pathways in glioblastoma multiforme.

Authors:  Joshua R D Pearson; Tarik Regad
Journal:  Signal Transduct Target Ther       Date:  2017-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.